# US 10,370,410 B2 · Cancer cell-targeting peptide and use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,370,410 B2 - Document ID: US10370410B2 - Status: Granted - Kind: B2 - Application number: 15/575,390 - Filed: 2016-05-18 - Published: 2018-06-07 - Granted: 2019-08-06 - Earliest claimed: 2015-05-18 - Assignees: Kyungpook National University Industry-Academic Cooperation Foundation - Applicants: Kyungpook National University Industry-Academic Cooperation Foundation - Inventors: Byung-Heon Lee; Hyun-Kyung Jung - Web page: https://patentgrep.com/patent/US10370410B2 ## CPC - C07K 7/06: having 5 to 11 amino acids - A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} - A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) - A61K 47/62: the modifying agent being a protein, peptide or polyamino acid - A61K 47/6911: {the form being a liposome} - G01N 33/575: for cancer - G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites} - G01N 33/58: involving labelled substances (G01N33/53 takes precedence) - A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract The present invention relates to a peptide targeting a tumor cell and use of the peptide, and more particularly, to a peptide consisting of SEQ ID NO: 1 to SEQ ID NO: 4 and specifically binding to a tumor cell, a composition including the peptide as an effective ingredient for detecting a tumor cell, a composition including the peptide as an effective ingredient for delivering a drug, and a composition including the peptide as an effective ingredient for imaging. The peptide of the present invention can be used for detection or imaging of a tumor cell in vitro and in vivo by specifically binding to a tumor cell. ## Claims ### Claim 1 A peptide targeting a tumor cell, the peptide consisting of any one amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO: 2. ### Claim 2 (depends on 1) A composition for delivering a drug specifically to a tumor cell, the composition including the peptide of claim 1 as an effective ingredient. ### Claim 3 (depends on 2) The composition of claim 2, wherein the drug is any one selected from the group consisting of paclitaxel, doxorubicin, vincristine, daunorubicin, vinblastine, actinomycin-D, docetaxel, etoposide, teniposide, bisantrene, homoharringtonine, imatinib mesylate, cisplain, 5-fluouracil, adriamycin, methotrexate, busulfan, chlorambucil, cyclophosphamide, melphalan, nitrogen mustard, nitrosourea, streptokinase, urokinase, alteplase, angiotensin II inhibitor, aldosterone acceptor inhibitor, erythropoietin, N-methyl-d-aspartate (NMDA) receptor inhibitor, Lovastatin, Rapamycin, Celebrex, Marimastat, and Trocade. ### Claim 4 A method of detecting a tumor cell, the method comprising: (a) mixing a peptide targeting the tumor cell with a sample, the peptide consisting of any one amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO: 4; (b) removing the peptide that is unbound or non-specifically bound; and (c) determining whether or not the peptide is bound and a binding position of the peptide. ### Claim 5 (depends on 4) The method of claim 4, wherein the tumor cell is caused by K-ras mutation. ### Claim 6 (depends on 4) The method of claim 4, wherein the peptide is labelled with one selected from a chromogenic enzyme, a radioactive isotope, a chromophore, a luminescent material, a fluorescer, a superparamagentic particle, and an ultrasuper paramagentic particle. ### Claim 7 (depends on 4) The method of claim 4, wherein tumor cell is any one selected from the group consisting of a lung tumor cell, a pancreatic cancer cell, a colorectal cancer cell, a biliary tract cancer cell, a gallbladder cancer cell, and a leukemic cell. ### Claim 8 (depends on 4) The method of claim 4, wherein the peptide is labelled with one selected from a chromogenic enzyme, a radioactive isotope, a chromophore, a luminescent material, a fluorescer, a superparamagentic particle, an ultrasuper paramagentic particle, and imaging the tumor cell. ### Claim 9 A method of selectively delivering a drug to a tumor cell in a subject, comprising: preparing a peptide selectively delivering the drug to the tumor cell, the peptide is consisting of any one amino acid sequence selected from the group consisting of SEQ ID NO: 3 to SEQ ID NO: 4; and administering the peptide associated with the drug to the subject. ### Claim 10 (depends on 9) The method of claim 9, wherein the drug is any one selected from the group consisting of paclitaxel, doxorubicin, vincristine, daunorubicin, vinblastine, actinomycin-D, docetaxel, etoposide, teniposide, bisantrene, homoharringtonine, imatinib mesylate, cisplain, 5-fluouracil, adriamycin, methotrexate, busulfan, chlorambucil, cyclophosphamide, melphalan, nitrogen mustard, nitrosourea, streptokinase, urokinase, alteplase, angiotensin II inhibitor, aldosterone acceptor inhibitor, erythropoietin, N-methyl-d-aspartate (NMDA) receptor inhibitor, Lovastatin, Rapamycin, Celebrex, Ticlopin, Marimastat, and Trocade.